Impact of the COVID-19 pandemic on European residency training programs in Physical and Rehabilitation Medicine: The point of -view of the International Society Of Physical and Rehabilitation Medicine World Youth Forum task force

Autor: Alessandro de Sire, Manoj K Poudel, Francesco Agostini, Margarida M Freitas, Alexander Ranker, Charlotte Rosselin, Karolína Sobotová, Walter R Frontera, Francesca Gimigliano

Publikováno v: The Journal of the International Society of Physical and Rehabilitation Medicine, Vol 3, Iss 4, Pp 131-136 (2020)

Coronavirus disease 2019 (COVID-19) has been declared a global public health emergency. The demand for services has altered the organization of medical services resulting in significant changes that have altered dramatically the education of resident

Externí odkaz: https://doaj.org/article/97abce6470864ef9b53a9208ff987eaf

Seroprevalence of Protective Antibodies Against Influenza and the Reduction of the Influenza Incidence Rate: An Annual Repeated Cross-Sectional Study From 2014 to 2019.

Autor: Guiomar R; National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal., Pereira da Silva S; Department of Epidemiology, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal., Costa I; National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal., Conde P; National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal., Cristóvão P; National Reference Laboratory for Influenza and Other Respiratory Viruses, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal., Rodrigues AP; Department of Epidemiology, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal., Fernandes A; Laboratório de Saúde Pública Dr.ª Laura Ayres, Faro, Portugal., Dias AP; Centro Hospitalar de Lisboa Ocidental, E. P. E., Lisbon, Portugal., Couto AR; Hospital de Santo Espírito da Ilha Terceira, E. P. E.R., Angra do Heroísmo, Portugal., Ramos A; Centro Hospitalar Universitário de São João, E. P. E., Porto, Portugal.; EPIUnit - Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal., Moita C; Unidade Local de Saúde da Guarda, E. P. E., Guarda, Portugal., Rodrigues C; Hospital do Espírito Santo de Évora, E. P. E., Évora, Portugal., Vale F; Unidade Local de Saúde da Guarda, E. P. E., Guarda, Portugal., Caldeira F; Hospital do Espírito Santo de Évora, E. P. E., Évora, Portugal., Bruges Armas J; Hospital de Santo Espírito da Ilha Terceira, E. P. E.R., Angra do Heroísmo, Portugal., Pereira-Vaz J; Centro Hospitalar e Universitário de Coimbra, E. P. E., Coimbra, Portugal., Alves J; Hospital Central e Universitário da Madeira, Funchal, Portugal., Freitas L; Hospital Central e Universitário da Madeira, Funchal, Portugal., Martins L; Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P. E., Lisbon, Portugal., Milho L; Laboratório de Saúde Pública Dr.ª Laura Ayres, Faro, Portugal., Mota-Vieira L; Hospital do Divino Espirito Santo de Ponta Delgada, E. P. E. R., Ponta Delgada, Portugal., Lopes L; Centro Hospitalar e Universitário de Lisboa Central, E. P. E., Lisbon, Portugal., Freitas M; Hospital da Senhora da Oliveira Guimarães, E. P. E., Guimarães, Portugal., Pessanha MA; Centro Hospitalar de Lisboa Ocidental, E. P. E., Lisbon, Portugal., Correia M; Centro Hospitalar e Universitário de Coimbra, E. P. E., Coimbra, Portugal., Marques MH; Centro Hospitalar Universitário do Porto, E. P. E., Porto, Portugal., Cardoso MJ; Centro Hospitalar Universitário de São João, E. P. E., Porto, Portugal., Peres MJ; Centro Hospitalar de Setúbal, E. P. E., Setúbal, Portugal., Cunha M; Instituto Português de Oncologia de Lisboa, Francisco Gentil, E.P. E., Lisbon, Portugal., Amantegui P; Centro Hospitalar Universitário Cova da Beira, E. P. E., Covilhã, Portugal., Mota P; Hospital da Senhora da Oliveira Guimarães, E. P. E., Guimarães, Portugal., Lopes P; Centro Hospitalar de Vila Nova de Gaia/Espinho, E. P. E., Vila Nova de Gaia, Portugal., Pereira P; Centro Hospitalar Universitário do Porto, E. P. E., Porto, Portugal., Viseu R; Centro Hospitalar de Setúbal, E. P. E., Setúbal, Portugal., Cabral R; Hospital do Divino Espirito Santo de Ponta Delgada, E. P. E. R., Ponta Delgada, Portugal., Côrte-Real R; Centro Hospitalar e Universitário de Lisboa Central, E. P. E., Lisbon, Portugal., Almeida S; Centro Hospitalar Universitário Cova da Beira, E. P. E., Covilhã, Portugal., Soares V; Centro Hospitalar de Vila Nova de Gaia/Espinho, E. P. E., Vila Nova de Gaia, Portugal., Mansinho K; Centro Hospitalar de Lisboa Ocidental, E. P. E., Lisbon, Portugal., Hungnes O; Norwegian National Influenza Centre, Norwegian Institute of Public Health, Oslo, Norway., Nunes B; Department of Epidemiology, National Institute of Health Dr. Ricardo Jorge, IP, Lisbon, Portugal.

Publikováno v: Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 May; Vol. 18 (5), pp. e13307.

Venous thromboembolism-related genetic determinant F11 rs4253417 is a potential prognostic factor in ischaemic stroke.

Autor: Tavares V; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP), Pathology and Laboratory Medicine Dep., Clinical Pathology SV, RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center (Porto.CCC), 4200-072, Porto, Portugal; ICBAS, Abel Salazar Institute for the Biomedical Sciences, 4050-313, Porto, Portugal; FMUP, Faculty of Medicine, University of Porto, 4200-072, Porto, Portugal., Assis J; Clinical Research Unit, Research Center of IPO Porto (CI-IPOP), RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center (Porto.CCC), 4200-072, Porto, Portugal., Pinto R; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP), Pathology and Laboratory Medicine Dep., Clinical Pathology SV, RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center (Porto.CCC), 4200-072, Porto, Portugal., Freitas-Silva M; FMUP, Faculty of Medicine, University of Porto, 4200-072, Porto, Portugal; Department of Medicine, Centro Hospitalar São João, 4200-319, Porto, Portugal., Medeiros R; Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP), Pathology and Laboratory Medicine Dep., Clinical Pathology SV, RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Center (Porto.CCC), 4200-072, Porto, Portugal; ICBAS, Abel Salazar Institute for the Biomedical Sciences, 4050-313, Porto, Portugal; FMUP, Faculty of Medicine, University of Porto, 4200-072, Porto, Portugal; Research Department, Portuguese League Against Cancer (NRNorte), 4200-172, Porto, Portugal; CEBIMED, Faculty of Health Sciences, Fernando Pessoa University, 4200-150, Porto, Portugal. Electronic address: ruimedei@ipoporto.min-saude.pt.

Publikováno v: Molecular and cellular probes [Mol Cell Probes] 2023 Aug; Vol. 70, pp. 101917. Date of Electronic Publication: 2023 Jun 27.

Risk factors among stroke subtypes and its impact on the clinical outcome of patients of Northern Portugal under previous aspirin therapy.

Autor: Freitas-Silva M; Department of Medicine, Centro Hospitalar São João, Porto, Portugal; FMUP, Faculty of Medicine, University of Porto, Porto, Portugal. Electronic address: m.corisca@gmail.com., Medeiros R; FMUP, Faculty of Medicine, University of Porto, Porto, Portugal; LPCC, Research Department Portuguese League Against Cancer (Liga Portuguesa Contra o Cancro-Núcleo Regional do Norte), Porto, Portugal; CEBIMED, Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal; Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese InstituteofOncologyof Porto (IPO-Porto), Porto, Portugal., Nunes JPL; Department of Medicine, Centro Hospitalar São João, Porto, Portugal; FMUP, Faculty of Medicine, University of Porto, Porto, Portugal.

Publikováno v: Clinical neurology and neurosurgery [Clin Neurol Neurosurg] 2021 Apr; Vol. 203, pp. 106564. Date of Electronic Publication: 2021 Feb 18.

Low density lipoprotein cholesterol values and outcome of stroke patients: influence of previous aspirin therapy.

Autor: Freitas-Silva M; Department of Medicine, Centro Hospitalar São João, Porto, Portugal.; FMUP, Faculty of Medicine, University of Porto, Porto, Portugal., Medeiros R; FMUP, Faculty of Medicine, University of Porto, Porto, Portugal.; LPCC, Research Department Portuguese League against Cancer (Liga Portuguesa Contra O Cancro, Núcleo Regional Do Norte), Porto, Portugal.; CEBIMED, Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal.; Molecular Oncology and Viral Pathology Group, IPO-Porto Research Center (CI-IPOP), Portuguese Institute of Oncology of Porto (Ipo-porto), Porto, Portugal., Nunes JPL; Department of Medicine, Centro Hospitalar São João, Porto, Portugal.; FMUP, Faculty of Medicine, University of Porto, Porto, Portugal.

Publikováno v: Neurological research [Neurol Res] 2020 Mar; Vol. 42 (3), pp. 267-274. Date of Electronic Publication: 2020 Feb 05.